2 Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors
Keyword(s):
Phase I
◽
2005 ◽
Vol 55
(5)
◽
pp. 497-501
◽